Malvern, PA — December 3, 2025 — Leads & Copy — Annovis Bio, Inc. (NYSE: ANVS) will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG) from December 4-6 in San Diego, California.
The presentation expands on Phase 3 Parkinson’s disease (PD) biomarker data, which indicates that patients with amyloid co-pathology experience more cognitive decline. This decline is counteracted and reversed by buntanetap. Buntanetap also reduces tau biomarkers in the same patients, which are known to increase with disease severity.
The presentation will also debut a cross-study comparison of trials, which will provide a comprehensive look at cognitive outcomes across all tested indications by Annovis. It will also highlight the population that benefits most—patients with amyloid pathology. In both Parkinson’s and Alzheimer’s diseases, individuals with biomarker-confirmed presence of amyloid experience the greatest cognitive gain following buntanetap. These findings further validate the drug’s mechanism as a translational inhibitor of neurotoxic aggregating proteins and support the Company’s next strategic steps.
Presentation details:
- Title: Amyloid co-pathology, cognitive decline, and improvement in buntanetap-treated Parkinson’s disease dementia patients
- Presenter: Maria Maccecchini, Ph.D., President and CEO
- Format: Poster guided tour
- Time of presentation: December 5, 6:15 p.m. PST
The data presented will be posted on the Company’s website following the conference.
The PSG Annual Meeting will bring together investigators, coordinators, trainees, advocates, and stakeholders to advance collaborative research and showcase advances and best practices in PD.
Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing therapies that improve patient outcomes and quality of life.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
Source: Annovis Bio
